Trials / Enrolling By Invitation
Enrolling By InvitationNCT06926621
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-670 | Solution for intravenous administration. |
Timeline
- Start date
- 2025-04-28
- Primary completion
- 2029-01-30
- Completion
- 2029-01-30
- First posted
- 2025-04-14
- Last updated
- 2026-02-27
Locations
11 sites across 5 countries: Australia, Belgium, Canada, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06926621. Inclusion in this directory is not an endorsement.